Sunshine Biopharma Enters $4M At-The-Market Sales Agreement

What Happened
Sunshine Biopharma Inc. announced on July 20, 2026 that it entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. Under the agreement the company may sell up to $4,000,000 of its common stock from time to time in “at-the-market” offerings through Aegis as exclusive sales agent. The shares will be issued under the company’s effective Form S-3 shelf registration (File No. 333-284142); a prospectus supplement was filed July 20, 2026. The company is not required to sell any shares, and Aegis is not required to buy or sell shares.

Key Details

• Agreement date: July 20, 2026; Agent: Aegis Capital Corp.
• Aggregate offering size: up to $4,000,000 of common stock.
• Agent fees: 3.0% commission on gross proceeds, plus reimbursement of certain expenses.
• Shares to be issued under the company’s Form S-3 (filed Jan 6, 2025; declared effective Jan 15, 2025); prospectus supplement filed July 20, 2026.
• The company agreed to indemnify the agent and to contribute to certain liabilities; either party may terminate the agreement.

Why It Matters
This ATM arrangement gives Sunshine Biopharma a flexible, market-based way to raise capital over time without a single large offering. For investors, potential share sales under the ATM could dilute existing shareholders if and when the company sells shares; proceeds will be reduced by the agent’s commission and expenses. The filing does not commit the company to sell shares or indicate timing or price—investors should review the prospectus supplement and monitor any actual sales announcements for details on dilution and use of proceeds.